Spots Global Cancer Trial Database for second line
Every month we try and update this database with for second line cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | NCT01491672 | Metastatic Rena... | RAD001 | 18 Years - | Novartis | |
| Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | NCT04008511 | Metastatic Colo... | Regorafenib Regorafenib Capecitabine Oxaliplatin | 18 Years - 75 Years | China Medical University, China | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | NCT00755534 | Colorectal Canc... | Irinotecan Capecitabine Cetuximab Oxaliplatin | 18 Years - 72 Years | Hellenic Oncology Research Group | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | NCT03495921 | Ewing Sarcoma Ewing Family of... Ewing's Tumor M... Ewing's Sarcoma... Ewing's Tumor R... Rare Diseases Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms, Bone... Neoplasms, Conn... Sarcoma, Ewing Neoplasms | Vigil Irinotecan Temozolomide | 2 Years - | Gradalis, Inc. | |
| Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy | NCT02403869 | Breast Neoplasm... | 18 Years - | Celgene | ||
| Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer | NCT01671332 | Carcinoma, Non ... | Docetaxel Suramin Docetaxel | 18 Years - | University of Wisconsin, Madison | |
| Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | NCT00660036 | Acute Myeloid L... | Gemtuzumab ozog... Mitoxantrone Etoposide | 18 Years - 70 Years | University of Pittsburgh | |
| Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | NCT04140318 | Advanced Gastri... | sintilimab nab-paclitaxel | 18 Years - 75 Years | ChineseAMS | |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | NCT03186326 | Metastatic Colo... MSI | FOLFOX regimen FOLFIRI Protoco... Avelumab Panitumumab Cetuximab Bevacizumab Aflibercept | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | NCT05879068 | SCLC | PM8002 Paclitaxel | 18 Years - | Biotheus Inc. | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer | NCT02401971 | Gastric Cancer | Thalidomide CPT-11 | 18 Years - 75 Years | Zhengzhou University | |
| mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line | NCT03464968 | Biliary Cancer ... | Oxaliplatin,5FU... irinotecan,5FU,... | 20 Years - | Seoul National University Bundang Hospital | |
| Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | NCT01813253 | Gastric Cancer Gastroesophagea... | Irinotecan Nimotuzumab | 20 Years - | Kuhnil Pharmaceutical Co., Ltd. | |
| Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | NCT01802749 | Recurrent Ovari... | Bevacizumab Paclitaxel Carboplatin pegylated lipos... Gemcitabine | 18 Years - | National Cancer Institute, Naples | |
| Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients | NCT03874000 | Non Small Cell ... | Sintilimab Metformin Hydro... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer | NCT05302778 | Breast Cancer Metastatic Brea... Triple Negative... | 18 Years - | University of Milano Bicocca | ||
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | NCT05712356 | Cholangiocarcin... Gallbladder Can... Gallbladder Car... Intrahepatic Ch... Extrahepatic Ch... Bile Duct Cance... Gall Bladder Ca... Gall Bladder Ca... | LSTA1 Durvalumab Cisplatin Gemcitabine FOLFOX regimen Placebo | 18 Years - | Lisata Therapeutics, Inc. | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | NCT00755118 | Colorectal Canc... | Oxaliplatin 5-Fluorouracil Leucovorin Bevacizumab Irinotecan Cetuximab | 18 Years - 72 Years | University Hospital of Crete | |
| Docetaxel and Irinotecan in Gastric Cancer | NCT04770623 | Stomach Cancer Gastric Cancer Chemotherapy Ef... | Docetaxel Irinotecan | 18 Years - 70 Years | Menoufia University | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer | NCT00690300 | Pancreas Neopla... | Docetaxel Oxaliplatin | 18 Years - | University of Ulm | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer | NCT00681876 | Colorectal Canc... | Irinotecan Avastin Erbitux | 18 Years - 72 Years | Hellenic Oncology Research Group | |
| A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | NCT01168973 | Non-Small Cell ... | Ramucirumab Placebo (for Ra... Docetaxel | 18 Years - | Eli Lilly and Company | |
| A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | NCT01168973 | Non-Small Cell ... | Ramucirumab Placebo (for Ra... Docetaxel | 18 Years - | Eli Lilly and Company | |
| Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer | NCT03986294 | Metastatic Panc... | S1 + Nal-IRI Nal-IRI+Leucovo... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | NCT01491672 | Metastatic Rena... | RAD001 | 18 Years - | Novartis | |
| The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | NCT00345059 | Advanced Non-Sm... | docetaxel vinorelbine gemcitabine capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy | NCT02403869 | Breast Neoplasm... | 18 Years - | Celgene | ||
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | NCT01491672 | Metastatic Rena... | RAD001 | 18 Years - | Novartis | |
| Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | NCT00660036 | Acute Myeloid L... | Gemtuzumab ozog... Mitoxantrone Etoposide | 18 Years - 70 Years | University of Pittsburgh | |
| A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | NCT02898077 | Gastroesophagea... Gastric Adenoca... | Ramucirumab Paclitaxel Placebo | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
